CAL
DSGN icon

Capital Advisors Ltd’s Design Therapeutics DSGN Stock Holding History

Capital Advisors Ltd’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Hold
12
– – ﹤0.01% 1417
2026
Q1 		$0 Hold
12
– – ﹤0.01% 1422
2025
Q4 		$0 Hold
12
– – ﹤0.01% 1403
2025
Q3 		$0 Hold
12
– – ﹤0.01% 1401
2025
Q2 		$0 Hold
12
– – ﹤0.01% 1399
2025
Q1 		$0 Hold
12
– – ﹤0.01% 1395
2024
Q4 		$0 Hold
12
– – ﹤0.01% 1424
2024
Q3 		$0 Hold
12
– – ﹤0.01% 1437
2024
Q2 		$0 Hold
12
– – ﹤0.01% 1446
2024
Q1 		$0 Buy
+12
New +$32 ﹤0.01% 1400

Other funds holding DSGN

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
APW
Allied Private Wealth Boca Raton, Florida $156M AUM
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Capital Advisors Ltd's DSGN Position: Q2 2026 in Review

Capital Advisors Ltd held its Design Therapeutics (DSGN) position steady in Q2 2026 at 12 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1417.

Capital Advisors Ltd first reported a position in DSGN in Q1 2024 and has held it in 10 quarters since. 9 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Capital Advisors Ltd held 12 shares of Design Therapeutics worth $0 as of Q2 2026.
  • Capital Advisors Ltd left its Design Therapeutics share count unchanged in Q2 2026.
  • Design Therapeutics made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #1417 holding.
  • Capital Advisors Ltd first reported a position in Design Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 9 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.